BridgeMD
New treatment option for Chronic Myelogenous Leukemia - Chronic Phase
Official title Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia
ClinicalTrials.gov ID: NCT06082804
What this study is testing
- What it's testing
- Chronic Myeloid Leukemia (CML) affects 820 people per year in France (2018), half of them are older than 60 years old. Tyrosine Kinase Inhibitors (TKI) are new kind of targeted therapy whose efficiency allow for a high rate of complete molecular response, leading to a disruption of treatment under certain conditions.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old.
- CML patient in chronic phase, eligible for oral therapy.
- Newly diagnosed CML and/or initiating oral therapy :
- Patient changing treatment for non-response or loss of therapeutic response or toxicities, on the condition that these toxicities are resolved or...
- Newly start of oral therapy.
You likely can't join if
- Patient that had a follow-up \> 3 months by an advanced practice nurse for CML before inclusion.
- Patient changing treatment for toxicities, if these toxicities are still \> grade I at inclusion.
- Patient enrolled in another treatment research protocol for CML.
- Pregnant women.
- Patient under legal protection, deprived of liberty or unable to be included in a research protocol.
See the full eligibility criteria
- Age ≥ 18 years old.
- CML patient in chronic phase, eligible for oral therapy.
- Newly diagnosed CML and/or initiating oral therapy :
- Patient changing treatment for non-response or loss of therapeutic response or toxicities, on the condition that these toxicities are resolved or grade I maximum at the time of inclusion.
- Newly start of oral therapy.
- Patient eligible to a follow-up by an advanced practice nurse.
- Patient capable to understand french and complete a questionnaire.
- Patient that had a follow-up \> 3 months by an advanced practice nurse for CML before inclusion.
- Patient changing treatment for toxicities, if these toxicities are still \> grade I at inclusion.
- Patient enrolled in another treatment research protocol for CML.
- Pregnant women.
- Patient under legal protection, deprived of liberty or unable to be included in a research protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Avignon, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Avignon, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.